Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia
IntroductionOlder patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. DNA methyltransferases (DNMTs) and histone-deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets. However, their effect...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-02-01
|
| Colección: | Frontiers in Immunology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1525110/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|